Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Clinical trial NCT00858234 · COMPLETED

Trial details

NCT number: NCT00858234
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2009-02-13
Primary completion: 2010-06-11
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.